4.2 Article

Familial dilated cardiomyopathy associated with pathogenic TBX5 variants: Expanding the cardiac phenotype associated with Holt-Oram syndrome

期刊

AMERICAN JOURNAL OF MEDICAL GENETICS PART A
卷 182, 期 7, 页码 1725-1734

出版社

WILEY
DOI: 10.1002/ajmg.a.61635

关键词

dilated cardiomyopathy; Holt-Oram syndrome; TBX5

向作者/读者索取更多资源

Holt-Oram syndrome (HOS) is a rare, autosomal dominant disorder caused by heterozygous pathogenic variants in cardiac T-box transcription factor, TBX5. Classically, it is associated with upper limb malformations and variable cardiac abnormalities. Limb manifestations are considered to be invariably present, ranging in severity from limitation in movement, to triphalangeal thumbs, absent thumbs, shortened forearms, or phocomelia. Cardiac involvement is characterized by congenital heart defects, most commonly septal structural malformations, and conduction system disease. Recently, novel TBX5 variants have also been reported in association with dilated cardiomyopathy (DCM). In this context, we report eight individuals from four unrelated families, in whom pathogenic variants in TBX5 segregated with an atypical HOS phenotype. Affected individuals exhibit relatively mild skeletal features of HOS, with a predominant cardiac phenotype, which includes several individuals affected by non-ischaemic DCM. To our knowledge, these represent the first reported cases of DCM in families with skeletal features of HOS, some of whom also harbored variants previously linked to a classical HOS phenotype (p. Arg279* and p.Arg237Gln). This finding supports diverse roles of TBX5 in cardiovascular development and function, and confirms the importance of long-term cardiac surveillance for individuals affected by HOS. Furthermore, these families highlight the wide phenotypic variability of HOS, which may include comparatively mild upper limb findings in respect to cardiac manifestations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Cardiac & Cardiovascular Systems

CardioScape mapping the cardiovascular funding landscape in Europe

Axel Radlach Pries, Anastasia Naoum, Helmut Habazettl, Mathias Dunkel, Robert Preissner, Caroline J. Coats, Ana Tornada, Francesco Orso, Frans Van de Werf, David A. Wood, Frans Van de Werf, David A. Wood, Sophie O'Kelly, James Craven, Andrew Coats, Karin Sipido, Dirk De Backer, Lars Wallentin, Gerd Hasenfuss, Luigi della Sala, Ilaria Leggeri, David A. Wood, Frans Van de Werf, Tiny Jaarsma, Perry Elliott, Axel Radlach Pries, Rosalinda Madonna, Keld Kjeldsen, Aldo P. Maggioni, Oscar H. Franco, Sarah Hills, Francesca Pugliese, Dirk De Bacquer

EUROPEAN HEART JOURNAL (2018)

Article Cardiac & Cardiovascular Systems

Peripartum cardiomyopathy: diagnosis and management

Alice M. Jackson, Jonathan R. Dalzell, Niki L. Walker, Caroline J. Coats, Pardeep S. Jhund, Mark C. Petrie

Editorial Material Cardiac & Cardiovascular Systems

The vital role of exercise testing in hypertrophic cardiomyopathy

Caroline J. Coats

INTERNATIONAL JOURNAL OF CARDIOLOGY (2018)

Article Cardiac & Cardiovascular Systems

Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy A Randomized Clinical Trial

Caroline J. Coats, Menelaos Pavlou, Oliver T. Watkinson, Alexandros Protonotarios, Linda Moss, Rebecca Hyland, Khadija Rantell, Antonis A. Pantazis, Maite Tome, William J. McKenna, Michael P. Frenneaux, Rumana Omar, Perry M. Elliott

JAMA CARDIOLOGY (2019)

Article Biochemical Research Methods

Identification of a Multiplex Biomarker Panel for Hypertrophic Cardiomyopathy Using Quantitative Proteomics and Machine Learning

Gabriella Captur, Wendy E. Heywood, Caroline Coats, Stefania Rosmini, Vimal Patel, Luis R. Lopes, Richard Collis, Nina Patel, Petros Syrris, Paul Bassett, Ben O'Brien, James C. Moon, Perry M. Elliott, Kevin Mills

MOLECULAR & CELLULAR PROTEOMICS (2020)

Letter Cardiac & Cardiovascular Systems

Hypertrophic Cardiomyopathy-Need for Gene-Specific Treatment? In Reply

Caroline J. Coats, Michael P. Frenneaux, Perry M. Elliott

JAMA CARDIOLOGY (2019)

Article Genetics & Heredity

Prenatal chromosome microarray: 'The UK experience'. A survey of reporting practices in UK genetic services (2012-2019)

Jenny Patterson, Diana Wellesley, Sian Morgan, Deirdre Cilliers, Stephanie Allen, Carol A. Gardiner

Summary: The diagnostic rate of prenatal CMA in the UK has shown improvement over time, with a pathogenic copy number variant identified in 7.8% of tests overall. Variants of uncertain significance (VUS) were reported in 0.7% of tests, and 'actionable' incidental findings in 0.12%. Reviewing survey responses at a national level highlights variations in testing experiences and practices, emphasizing the need for future guideline development and implementation of novel techniques such as prenatal whole exome sequencing.

PRENATAL DIAGNOSIS (2021)

Article Urology & Nephrology

Genetic evaluation of paediatric nephrocalcinosis: phenotype-driven genetic panels reveal a rare diagnosis

Jenny Patterson, Zoe Jacob, Ben C. Reynolds

Summary: Monogenic causes of paediatric nephrocalcinosis can present with extensive phenotypic variability. In this case, a 14-year-old male with incidentally identified nephrocalcinosis alongside growth impairment and dental anomalies was confirmed to have Bartter syndrome type II through genetic investigation. The presence of amelogenesis imperfecta is rare in inherited tubulopathies, making this case exceptional in its presentation. The utility of a phenotype-driven genetic panel in resolving atypical presentations of nephrocalcinosis is highlighted, allowing for precise diagnosis, tailored therapy, and prognostication.

CLINICAL KIDNEY JOURNAL (2022)

Editorial Material Medicine, Research & Experimental

Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK

Julian D. Gillmore, Mary M. Reilly, Caroline J. Coats, Rob Cooper, Helen Cox, Mark R. E. Coyne, Andrew J. Green, Ruth McGowan, William E. Moody, Philip N. Hawkins

Summary: Diagnosing hereditary transthyretin-mediated amyloidosis (hATTR) is challenging due to the heterogeneity of clinical presentation. The TTR gene variant and its penetrance in each individual play a significant role in the clinical manifestations. There are specific TTR variants seen most commonly in the UK and Ireland, which require special consideration for diagnosis and genetic testing. A multidisciplinary panel of experts from the UK and Ireland developed a consensus statement, providing recommendations for diagnosis, screening, and management of hATTR, depending on the symptoms and genetic variants.

ADVANCES IN THERAPY (2022)

Review Cardiac & Cardiovascular Systems

History of the British Cardiovascular Society

Caroline J. Coats

Summary: The British Cardiovascular Society celebrates its centenary in 2022. It started as a small group of physicians interested in heart disease and has now grown into a professional organization representing cardiovascular care and research. The article outlines the history of the organization and discusses the impact of scientific and technological innovations on the medical world. It emphasizes the importance of addressing service needs, healthcare professionals, and healthcare policies, as well as improving healthcare standards.
Review Cardiac & Cardiovascular Systems

Cardiac care of children with dystrophinopathy and females carrying DMD-gene variations

John Bourke, Cathy Turner, William Bradlow, Ashish Chikermane, Caroline Coats, Matthew Fenton, Maria Ilina, Alexandra Johnson, Stam Kapetanakis, Lisa Kuhwald, Adrian Morley-Davies, Ros Quinlivan, Konstantinos Savvatis, Marianela Schiava, Zaheer Yousef, Michela Guglieri

Summary: This study provides concise evidence-based and/or consensus-based best practice guidance for cardiac care in children with DMD and recommendations for screening and management of female carriers of DMD gene mutations. These guidelines aim to improve heart health in DMD patients and promote uniform and high-level care through timely interventions.

OPEN HEART (2022)

Article Cardiac & Cardiovascular Systems

Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

Martin S. Maron, Ahmad Masri, Lubna Choudhury, Iacopo Olivotto, Sara Saberi, Andrew Wang, Pablo Garcia-Pavia, Neal K. Lakdawala, Sherif F. Nagueh, Florian Rader, Albree Tower-Rader, Aslan T. Turer, Caroline Coats, Michael A. Fifer, Anjali Owens, Scott D. Solomon, Hugh Watkins, Roberto Barriales-Villa, Christopher M. Kramer, Timothy C. Wong, Sharon L. Paige, Stephen B. Heitner, Stuart Kupfer, Fady I. Malik, Lisa Meng, Amy Wohltman, Theodore Abraham

Summary: This study evaluated the safety and efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM). The results showed that aficamten significantly reduced left ventricular outflow tract gradients and improved clinical symptoms.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)

Article Cardiac & Cardiovascular Systems

Proteomic Analysis of the Myocardium in Hypertrophic Obstructive Cardiomyopathy

Caroline J. Coats, Wendy E. Heywood, Alex Virasami, Nadia Ashrafi, Petros Syrris, Cris dos Remedios, Thomas A. Treibel, James C. Moon, Luis R. Lopes, Christopher G. A. McGregor, Michael Ashworth, Neil J. Sebire, William J. McKenna, Kevin Mills, Perry M. Elliott

CIRCULATION-GENOMIC AND PRECISION MEDICINE (2018)

暂无数据